The program aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with bleeding disorders, and the gap between the amount of treatment product needed versus what is available.
GAP partners include CSL Behring, Baxter, Bayer, Biogen Idec Hemophilia, Biotest, Pfizer, Talecris, the Irish Hemophilia Society, the Jan Willem Andre de la Porte Family Foundation, and the World Health Organization (WHO).
Sixteen countries have participated in GAP: Armenia, Azerbaijan, Belarus, China, Ecuador, Egypt, Georgia, Jordan, Lebanon, Mexico, Peru, Philippines, Russia, Syria, Thailand, and Tunisia.
About the World Federation of Hemophilia The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and other inherited bleeding disorders.
Since it was established in 1963, the WFH has grown into a truly global network with member organizations in 118 countries and official recognition from the World Health Organization. It works in partnership with healthcare professionals and people with hemophilia, governments and regulators, industry and foundations, to improve care for people with bleeding disorders throughout the world. For more information, visit www.wfh.org.
About CSL Behring CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare an
|SOURCE CSL Behring|
Copyright©2010 PR Newswire.
All rights reserved